Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has received an average recommendation of “Hold” from the ten analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $9.33.

FULC has been the topic of a number of research analyst reports. Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. Bank of America lowered shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price objective for the company from $10.00 to $2.00 in a research note on Thursday, September 12th. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $22.00 to $3.00 in a research note on Thursday, September 12th. Leerink Partners restated a “market perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, September 12th. Finally, HC Wainwright restated a “neutral” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, November 14th.

Fulcrum Therapeutics Price Performance

NASDAQ FULC opened at $3.25 on Wednesday. Fulcrum Therapeutics has a 12 month low of $2.86 and a 12 month high of $13.70. The firm has a market capitalization of $175.30 million, a PE ratio of -10.48 and a beta of 2.24. The company’s 50 day simple moving average is $3.41 and its 200 day simple moving average is $6.32.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FULC. SG Americas Securities LLC acquired a new position in Fulcrum Therapeutics in the 1st quarter worth approximately $115,000. Vanguard Group Inc. boosted its stake in shares of Fulcrum Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company’s stock valued at $23,965,000 after buying an additional 18,681 shares during the period. Jane Street Group LLC boosted its stake in shares of Fulcrum Therapeutics by 54.3% during the 1st quarter. Jane Street Group LLC now owns 535,062 shares of the company’s stock valued at $5,051,000 after buying an additional 188,212 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Fulcrum Therapeutics during the 2nd quarter valued at $3,084,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Fulcrum Therapeutics during the 2nd quarter valued at $1,158,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.